Launch Of Novel Immunodiagnostics Tests Opens New Doors To Treat Chronic Diseases

There have been significant advances in immunodiagnostics during the last couple of years. Since the emergence of new diagnostic technologies, the demand and availability of novel diagnostic platforms and immunoassay formats. The efforts by researchers during the last couple of decades resulted into the development of potential antibodies for wide range of analytes.

According to Allied Market Research, the immunodiagnostics market is expected to reach $17.83 Billion by 2022, growing at a CAGR of 7.3% from 2016 to 2022. That’s because of rapid growth in preference of automated and next-generation immunodiagnostics platforms. However, high cost of immunodiagnostic products has been the greatest challenge for the market players. On the contrary, the use of smartphone for immunodiagnostics, smartphone-based immunoassays and integrated reader have helped deal with the high cost of immunodiagnostics. In addition, smartphones that are equipped with high-resolution cameras, GPRS, iCloud computing, and advanced processors have been essentials for next-generation immunodiagnostics devices, mobile healthcare, and telemedicine.

The ongoing Covid-19 pandemic has increased the growth of the immunodiagnostics market as there is a sudden increase in the demand for faster antigen tests. Keeping it in mind, Ortho Clinical Diagnostics, an in vitro diagnostics company, recently launched a Covid-19 antibody test that offers 100% specificity and greater choice in tracking, patient management, and screening of convalescent plasma. The test is expected to help healthcare professionals to understand whether the patient has been exposed to the Covid-19 virus.

Similarly, DiaSorin, an Italian biotech company, recently announced to launch fully-automated serology tests to detect Covid-19 antibodies in the patients. The company’s studies showed support for the launch of high-processing volume tests that detect antibodies in Covid-19 patients. The test is designed to detect IgG antibodies against the SARS-CoV-2 virus spike protein. The test is developed to detect those people who have already been infected with virus and whose diagnostics has not been performed by molecular diagnostic test and swab test. The company now aims to get the CE mark and emergency use of authorization from the Food and Drug Administration.

Since the outbreak of Covid-19, several companies have invested a huge amount of money and workforce in studying various respiratory diseases. For instance, Oncimmune Holdings, a leading immunodiagnostics group, recently initiated a study to support adoption of Oncimmune’s EarlyCDT® Lung blood test. The study will also focus on understanding the economic impact of tests in treatment choices and on overall healthcare costs in the U.S.

Apart from this, Immunodiagnostic Systems, a renowned Laboratory diagnostics specialist, recently launched four new “i-Tracker’ assays that are developed to run on the automated analyzer. The company stated that its partner Theradiag would develop the assays, ‘i-Tracker Infliximab’, ‘i-Tracker Adalimumab’, ‘i-Tracker Anti-Infliximab’, and ‘i-Tracker Anti-Adalimumab’. These four tests are expected to complement the company’s focus on treating and diagnosing auto-immune diseases as therapeutic drug monitoring is performed by the same immunology teams.

The launch of new tests to detect novel coronavirus, auto-immune diseases, and other respiratory diseases has increased the growth of the immunodiagnostics market. With the adoption of various advanced technologies and the adoption of telemedicine, the opportunities are surely limitless.

Related Post